The benefits of treating osteoporosis in postmenopausal women outweigh the perceived risks, according to a Clinical Practice Guideline issued today by the Endocrine Society. The Society introduced the guideline during a news conference on Monday at ENDO 2019, its annual meeting in New Orleans, La.
The guideline, titled “Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline,” was published online and will appear in the May 2019 print issue of The Journal of Clinical Endocrinology & Metabolism (JCEM), a publication of the Endocrine Society. The guideline provides evidence for the benefits of treating postmenopausal women with osteoporosis. The recommendations cover the newest, most effective medication options and answer patient questions regarding the duration of therapy and monitoring.
One in two postmenopausal women will break a bone due to osteoporosis in their lifetime, making them at high risk for subsequent fractures, yet many of these women do not receive treatment. With ongoing reports of atypical femoral fractures and osteonecrosis of the jaw, patients and providers are uncertain about the benefits and risks of treating osteoporosis. In fact, there has been a decline in the use of bisphosphonates and an increase in hip fractures among postmenopausal women.
“There is a considerable gap in the treatment of osteoporosis. Most women will not take anti-osteoporosis therapies despite their efficacy, and those that do often stop. As a result, the rate of hip fractures has leveled off and may be increasing. In addition, bone density screening has declined precipitously,” said Clifford J. Rosen, M.D., director, Center for Clinical and Translational Research at the Maine Medical Center Research Institute in Scarborough. Rosen chaired the writing committee that developed the guideline.
“We hope our guideline will not only improve patient care but provide confidence in treatment,” he said.
Recommendations from the guidelines which were derived from two evidence-based reviews include:
- Treating postmenopausal women at high risk of fractures, especially those who have experienced a recent fracture, with pharmacological therapies, as the benefits outweigh the risks.
- Prescribing initial treatment with bisphosphonates to reduce fracture risk.
- Reassessing fracture risk after three to five years in women taking bisphosphonates. Women who remain at high risk of fractures should continue therapy, while those who are at low-to-moderate risk of fractures should be considered for a “bisphosphonate holiday.”
- Using denosumab as an alternative to bisphosphonates for the initial treatment of high-risk individuals.
Other members of the Endocrine Society writing committee that developed this guideline include: Richard Eastell of the University of Sheffield in Sheffield, United Kingdom; Dennis M. Black of the University of California San Francisco in San Francisco, Calif.; Angela M. Cheung of University of Toronto in Toronto, Canada; M. Hassan Murad of the Mayo Clinic Evidence Based Practice Center in Rochester, Minn.; and Dolores Shoback of the San Francisco Veterans Affairs Medical Center in San Francisco, Calif.
The Society established the Clinical Practice Guideline Program to provide endocrinologists and other clinicians with evidence-based recommendations in the diagnosis, treatment, and management of endocrine-related conditions. Each guideline is created by a writing committee of topic-related experts in the field. Writing committees rely on evidence-based reviews of the literature in the development of guideline recommendations. The Endocrine Society does not solicit or accept corporate support for its guidelines. All Clinical Practice Guidelines are supported entirely by Society funds.